SC5b-9 Level

Your immune system has an ancient arm that ends a fight by punching microscopic holes in a target cell until it bursts. This test catches the debris left behind when that final step fires, so it tells you whether the hole-punching machinery is running when your body should be calm.

That debris shows up in a striking range of illnesses, from severe COVID-19 to certain kidney and blood disorders, and higher levels usually mean sicker people. What it cannot do is name the illness on its own, which is why this remains a research and specialty marker rather than a routine screen.

What This Test Actually Measures

SC5b-9 (soluble C5b-9, also called the soluble terminal complement complex) is the free-floating fragment left behind when the complement system runs to its last step. The complement system is a chain of blood proteins that tag and destroy invaders. Its final act builds a ring that drills into a cell membrane.

When that ring starts to form in the bloodstream instead of on a target, two carrier proteins cap it and it is released as this soluble fragment. Because the fragment only appears when the whole chain fires to completion, a high level is a direct readout that this activation is happening somewhere in the body. It does not say where, and the fragment itself has no known job once released. It is a marker, not an actor.

Severe Infection and COVID-19

In COVID-19, levels climb with severity, running roughly two to three times higher in severe disease than in healthy people. The level measured on admission predicts who goes on to respiratory failure and a worse outcome, and it does so even in patients who look mild and even when standard inflammatory signals are not raised.

The number falls again as people recover, normalizing within a month in a large share of patients. That pattern, high during the storm and dropping in recovery, is the recurring theme of this marker across diseases.

Sepsis and Dangerous Clotting

In sepsis, the level tracks with severity, with the widespread clotting complication doctors call disseminated intravascular coagulation, with the need for blood-pressure support, and with death. Patients with that clotting complication ran higher than those without it, and the highest group had about a one in three chance of dying in hospital.

There is a catch worth knowing. In the very sickest sepsis, the complement system is already so maxed out that the number loses its power to predict who does better or worse. A ceiling has been hit, and more activation no longer separates patients.

Stem Cell Transplant Complications

The evidence here is strongest in children. After a stem cell transplant, an early rise in the marker flags transplant-associated thrombotic microangiopathy, a dangerous clotting injury to small blood vessels, before it becomes obvious. In one pediatric validation study it caught every case that later developed, though it also flagged many who did not.

In adults the picture is less settled. One 2026 cohort found that combining the marker, measured around day 14, with a separate score of blood-vessel stress sorted adults into low, middle, and high risk, with the high-risk group facing roughly a one in three chance of the complication within 100 days versus about one in fifty for the low-risk group. But another large 2026 adult study found no association between the marker and the complication, so the adult prognostic value remains uncertain. Scheduled, serial testing has shown the most promise in children.

Heart Attack and Heart Failure

The complex surges within hours of a heart attack. In a study of 725 people treated for a major heart attack, higher levels independently predicted death and future cardiovascular events, meaning the link held after accounting for other risk factors. In heart failure combined with high blood pressure, very high levels were tied to roughly five and a half times the risk of dying.

For telling a specific type of heart attack apart from healthy controls, the marker is only a moderate discriminator on its own, so it works better as an added layer than as a standalone test.

Autoimmune Disease Activity

In active lupus, the marker tracks disease activity more sensitively than the routine complement tests. In immune platelet loss (immune thrombocytopenic purpura), it rises during acute flares and falls in remission, moving in the opposite direction to the platelet count. In the small-vessel inflammation of Henoch-Schonlein purpura, it follows flares while the standard complement panel stays normal.

In anti-glomerular basement membrane disease, a severe autoimmune attack on the kidney, the blood level predicted which patients progressed to kidney failure during follow-up.

Kidney Disease

In C3 glomerulopathy, a complement-driven kidney disease, the blood level together with the C3 pattern independently predicted who progressed to kidney failure. In type 1 diabetes, about two thirds of patients had elevated plasma levels that tracked with early markers of kidney and blood-vessel damage.

One caution: much of the kidney research measures this fragment in urine rather than blood, and the two are different measurements. Urinary levels reflect what is happening inside the kidney filter, which the blood test does not capture in the same way.

Why One Reading Tells You Little

This is a moving activity signal, not a fixed trait. It climbs during flares and falls in remission, with COVID-19 levels normalizing within a month in many people and post-transplant levels peaking around day 28 and returning toward baseline by day 100. A single value is a snapshot of one moment.

The trajectory is what carries information: whether the number is climbing, holding, or settling tells you far more than one reading in isolation. Get a baseline, then, if you are tracking a known condition, retest on the schedule your specialist sets. For a general baseline in a well person, repeating at least yearly or whenever symptoms change is reasonable, using the same lab each time.

What an Unexpected Result Should Prompt

Because a high value is non-specific, the next move is to read it against context rather than act on it alone. An isolated mild elevation in someone who feels well, especially soon after an infection, injury, or surgery, usually calls for a repeat and a watchful eye rather than alarm.

Pair the result with the standard complement tests (C3, C4, and CH50), a blood count, kidney function, and a marker of red-cell breakdown; add a test of ADAMTS13 activity when a clotting microangiopathy is on the table, since it separates one serious cause from another. The pattern that demands urgency is a rising complement signal alongside falling platelets, rising red-cell breakdown, and kidney injury. Depending on the picture, the right specialist is a nephrologist, a hematologist, or an immunologist.

When Normal Does Not Mean Safe, and Treatment May Not Lower the Number

Two findings run against the obvious reading of this test, and both resolve the same way. First, a low or normal blood level does not clear you of complement-driven disease, because complement can be consumed or deposited in tissue rather than left circulating; in preeclampsia, for example, the blood level can be low while the urine level is high, and in the sickest sepsis the blood value plateaus. Second, the main complement-blocking drug does not lower the blood number reliably: depending on the assay used, the value may fall substantially or stay high, because the drug forms inactivated complexes that some lab assays still count.

The way to hold both facts together is to stop treating this as a simple good-number, bad-number test. It is an activity readout, and its meaning depends on where complement is acting and what treatment is on board. A normal blood value with tissue disease, and a value that does not track the drug's effect on effective treatment, are not contradictions once you see the marker that way.

Why a Single Reading Can Fool You

• Sample handling: complement keeps activating inside the tube after the draw, so without the right anticoagulant, prompt processing, and careful freezing, the number reads falsely high.
• Complement-blocking drugs (eculizumab, ravulizumab): depending on the assay, these drugs may lower the value substantially or leave it high, because some assays still count the inactivated complexes the drugs create, so a circulating level alone is not a reliable check that the drug is working.
• Any acute hit: infection, major trauma, surgery, and cardiac arrest all raise the level transiently, regardless of whether you have a chronic complement problem.
• Lab-to-lab differences: assays, calibrations, and even units vary between labs, so absolute numbers are not comparable across them.